Logo
x

Search

Subscribe Now

T2D

AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for the Treatment of Chronic Kidney Disease in Patients with and without T2D

AstraZeneca's Forxiga (dapagliflozin) Receives EC's Approval for the Treatment of Chronic Kidney Disease in Patients with and with...

  • August 9, 2021
Novo Nordisk Receives the US FDA's Refusal to File Letter for Semaglutide to Treat T2D

Novo Nordisk Receives the US FDA's Refusal to File Letter for Semaglutide to Treat T2D

  • March 23, 2021
Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

Bayer Reports the US FDA's Acceptance of NDA and Grants Priority Review for Finerenone (BAY 94-8862) to Treat CKD and T2D

  • January 13, 2021
Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D

Teladoc Health and Dexcom Offers CGM-Powered Insight for T2D

  • January 13, 2021
Novo Nordisk Reports Submission of Label Extension Application to the EMA for Semaglutide (once weekly- 2.0 mg) for T2D

Novo Nordisk Reports Submission of Label Extension Application to the EMA for Semaglutide (once weekly- 2.0 mg) for T2D

  • December 30, 2020
Bayer Reports Regulatory Submission of Finerenone (BAY 94-8862) to the US and EU for CKD and T2D

Bayer Reports Regulatory Submission of Finerenone (BAY 94-8862) to the US and EU for CKD and T2D

  • November 10, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.